1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) Nov 18 - Nov 20, 2024 Supporting Materials Trial in Progress COVALENT-111: A Phase 2 Trial of the Oral Menin Inhibitor Icovamenib (BMF-219) in Patients with Type 2 Diabetes (Oral Presentation: November 19 at 12:45 – 12:50 SGT) 216.2 KB Late-Breaker: Assessment of Icovamenib (BMF-219) in Persons with Poorly Controlled Severe Insulin-Deficient (SIDD) Type 2 Diabetes (T2D): COVALENT-111 Case Studies (Oral Presentation: November 19 at 12:50 – 12:55 SGT) 615.2 KB Unlocking the Potential of Menin Inhibition: Icovamenib and a Look into the Future of Diabetes Management (Industry Symposium: November 19 at 17:10 – 18:10 SGT) 7.1 MB Watch the replay Trial in Progress COVALENT-112: A Phase 2 Trial of the Oral Menin Inhibitor Icovamenib (BMF-219) in Type 1 Diabetes (Oral Presentation: November 20 at 11:25 - 11:35 SGT) 1.9 MB
Trial in Progress COVALENT-111: A Phase 2 Trial of the Oral Menin Inhibitor Icovamenib (BMF-219) in Patients with Type 2 Diabetes (Oral Presentation: November 19 at 12:45 – 12:50 SGT) 216.2 KB
Late-Breaker: Assessment of Icovamenib (BMF-219) in Persons with Poorly Controlled Severe Insulin-Deficient (SIDD) Type 2 Diabetes (T2D): COVALENT-111 Case Studies (Oral Presentation: November 19 at 12:50 – 12:55 SGT) 615.2 KB
Unlocking the Potential of Menin Inhibition: Icovamenib and a Look into the Future of Diabetes Management (Industry Symposium: November 19 at 17:10 – 18:10 SGT) 7.1 MB
Trial in Progress COVALENT-112: A Phase 2 Trial of the Oral Menin Inhibitor Icovamenib (BMF-219) in Type 1 Diabetes (Oral Presentation: November 20 at 11:25 - 11:35 SGT) 1.9 MB
